1. A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm

   • Giovanni Paganelli
   • Lisa Bodei
   • Irvin Modlin

   Editorial 20 June 2020 Pages: 2223 - 2226

   

2. Metastatic melanoma: can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?

   • Elif Hindié

   Editorial 22 April 2020 Pages: 2227 - 2232

3. Anatomy of ¹⁸F-GE180, a failed radioligand for the TSPO protein

   • Paolo Zanotti-Fregonara
   • Belen Pascual
   • Federico Turkheimer

   Letter to the Editor 22 February 2020 Pages: 2233 - 2236

   

4. In response to: Anatomy of ¹⁸F-GE180, a failed radioligand for the TSPO protein

   • Nathalie L. Albert
   • M. Unterrainer
   • P. Bartenstein

   Letter to the Editor Open access 10 June 2020 Pages: 2237 - 2241

   

5. 18F-GE180, a radioligand for the TSPO protein: not ready for clinical trials in multiple sclerosis

   • Richard Nicholas
   • David Brooks
   • David Owen

   Letter to the Editor 08 May 2020 Pages: 2242 - 2243

6. The added benefit of contrast-enhanced CT in evaluation of incidental FDG-avid colon lesions

   • Joseph C. Lee
   • Gemma F. Hartnett
   • Aravind S. Ravi Kumar

   Letter to the Editor 12 February 2020 Pages: 2244 - 2244

7. Reply to Letter to the Editor: “The added benefit of contrast-enhanced CT in the evaluation of incidental FDG-avid colon lesions”

   • Julian Kirchner
   • Benedikt M. Schaarschmidt
   • Philipp Heusch

   Letter To The Editor & Reply Open access 30 June 2020 Pages: 2245 - 2246

8. Re: ¹⁸F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial

   • Shintaro Akiyama
   • Cindy Traboulsi
   • David T. Rubin

   Letter to the Editor 02 April 2020 Pages: 2247 - 2247

9. CTumorGAN: a unified framework for automatic computed tomography tumor segmentation

   • Shuchao Pang
   • Anan Du
   • Guanfeng Liu

   Original Article 28 March 2020 Pages: 2248 - 2268

   

10. Evaluation of improved attenuation correction in whole-body PET/MR on patients with bone metastasis using various radiotracers

    • Hong Grafe
    • Maike E. Lindemann
    • Harald H. Quick

    Original Article Open access 03 March 2020 Pages: 2269 - 2279

    

11. Dynamic PET/CT imaging of ¹⁸F-(2S, 4R)4-fluoroglutamine in healthy volunteers and oncological patients

    • Xiaoxia Xu
    • Hua Zhu
    • Zhi Yang

    Original Article 12 March 2020 Pages: 2280 - 2292

    

12. Dynamic whole-body ¹⁸F-FDG PET for differentiating abnormal lesions from physiological uptake

    • Motoki Nishimura
    • Nagara Tamaki
    • Kei Yamada

    Original Article 18 March 2020 Pages: 2293 - 2300

    

13. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4

    • Romain-David Seban
    • Antoine Moya-Plana
    • Laurent Dercle

    Original Article 23 March 2020 Pages: 2301 - 2312

    

14. Influence of ¹⁸F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach

    • Susann-Cathrin Olthof
    • Andrea Forschner
    • Christina Pfannenberg

    Original Article 02 March 2020 Pages: 2313 - 2321

    

15. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

    • Justin Ferdinandus
    • John Violet
    • Michael S. Hofman

    Short Communication 05 March 2020 Pages: 2322 - 2327

    

16. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [⁶⁸Ga]PSMA-PET-guided metastasis-directed therapy

    • Marco M. E. Vogel
    • Stephanie G. C. Kroeze
    • Stephanie E. Combs

    Original Article Open access 16 March 2020 Pages: 2328 - 2338

    

17. Interobserver variability, detection rate, and lesion patterns of ⁶⁸Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy

    • Jonathan Miksch
    • Dirk Bottke
    • Vikas Prasad

    Original Article Open access 10 March 2020 Pages: 2339 - 2347

    

18. A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma

    • Jennifer E. Gains
    • Veronica Moroz
    • Mark N. Gaze

    Original Article 11 March 2020 Pages: 2348 - 2357

    

19. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice

    • Vikas Prasad
    • Raj Srirajaskanthan
    • Lisa Bodei

    Original Article Open access 15 February 2020 Pages: 2358 - 2371

    

20. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with ¹⁷⁷Lu-Dotatate: an analysis of the NETTER-1 study

    • Jonathan Strosberg
    • Pamela L. Kunz
    • on behalf of the NETTER-1 study group

    Original Article Open access 02 March 2020 Pages: 2372 - 2382

    

21. Deep learning-based attenuation map generation for myocardial perfusion SPECT

    • Luyao Shi
    • John A. Onofrey
    • Chi Liu

    Original Article 26 March 2020 Pages: 2383 - 2395

    

22. Extracardiac soft tissue uptake, evidenced on early ^99mTc-HMDP SPECT/CT, helps typing cardiac amyloidosis and demonstrates high prognostic value

    • Nathan Malka
    • Mukedaisi Abulizi
    • Thibaud Damy

    Original Article 10 March 2020 Pages: 2396 - 2406

    

23. High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson’s disease cohort

    • Patrik Fazio
    • Daniel Ferreira
    • Andrea Varrone

    Original Article Open access 04 February 2020 Pages: 2407 - 2416

    

24. Prediction of lithium treatment response in bipolar depression using 5-HTT and 5-HT_1A PET

    • Mala Ananth
    • Elizabeth A. Bartlett
    • Chuan Huang

    Original Article 13 February 2020 Pages: 2417 - 2428

    

25. PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [¹⁸F]PF-06684511

    • Ryosuke Arakawa
    • Akihiro Takano
    • Andrea Varrone

    Original Article Open access 06 March 2020 Pages: 2429 - 2439

    

26. Multiparametric imaging hippocampal neurodegeneration and functional connectivity with simultaneous PET/MRI in Alzheimer’s disease

    • Shaozhen Yan
    • Chaojie Zheng
    • Jie Lu

    Original Article Open access 10 March 2020 Pages: 2440 - 2452

    

27. Ventilation/perfusion SPECT/CT findings in different lung lesions associated with COVID-19: a case series

    • Nina Cobes
    • Mohamed Guernou
    • Jean-François Grellier

    Short Communication 18 June 2020 Pages: 2453 - 2460

    

28. Abnormalities at three musculoskeletal sites on whole-body positron emission tomography/computed tomography can diagnose polymyalgia rheumatica with high sensitivity and specificity

    • Claire E. Owen
    • Aurora M. T. Poon
    • Russell R. C. Buchanan

    Original Article 23 February 2020 Pages: 2461 - 2468

    

29. Lymphangioleiomyomatosis revealed by ⁶⁸Ga-NOTA-Evans Blue PET/CT

    • Guozhu Hou
    • Wenshuai Xu
    • Wuying Cheng

    Image of the Month 10 January 2020 Pages: 2469 - 2470

    

30. Tuberous sclerosis complex (TSC) with epilepsy on ¹⁸F-FDG simultaneous PET/MR

    • Siwei Liu
    • Yang Cai
    • Hongcheng Shi

    Image of the Month 17 January 2020 Pages: 2471 - 2472

    

31. Segmental complex regional pain syndrome of the thumb

    • Malik Juweid
    • Salem AlYasjeen
    • Aws Kanfar

    Image of the Month 28 January 2020 Pages: 2473 - 2475

    

32. COVID-19 pneumonia: increased choline uptake with 18F-choline PET/CT

    • Laura Olivari
    • Niccolò Riccardi
    • Matteo Salgarello

    Image of the Month 04 June 2020 Pages: 2476 - 2477

    

33. PET/MR and PET/CT in a severe COVID-19 patient

    • Xiaochen Li
    • Yan Wang
    • Meiyun Wang

    Image of the Month 04 June 2020 Pages: 2478 - 2479

    

34. Correction to: Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes

    • Jun Pyo Kim
    • Jeonghun Kim
    • Joon-Kyung Seong

    Correction 27 June 2020 Pages: 2480 - 2480

35. Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

    • E. J. van Helden
    • S. G. Elias
    • C. W. Menke-van der Houven van Oordt

    Correction 13 June 2020 Pages: 2481 - 2481